HSDT - Helius Medical Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.30
-0.21 (-2.47%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.51
Open8.55
Bid0.00 x 800
Ask0.00 x 1100
Day's Range8.10 - 8.55
52 Week Range7.15 - 13.20
Volume58,829
Avg. Volume96,487
Market Cap214.28M
Beta (3Y Monthly)-0.53
PE Ratio (TTM)N/A
EPS (TTM)-1.27
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire15 days ago

    Helius Medical Technologies, Inc. Announces Fourth Partnership to Implement Clinical Experience Programs with PoNS™ Treatment in the United States

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, has partnered with Kessler Institute for Rehabilitation and Kessler Foundation, New Jersey-based leaders in rehabilitation care and research, to implement its fourth Clinical Experience Program (CEP) for its Portable Neuromodulation Stimulator (PoNS™). PoNS is a licensed class II medical device in Canada and an investigational medical device in the U.S. and in the EU. PoNS is currently under review for US market clearance by the Food & Drug Administration (FDA) and EU clearance by the EU Notified Body.

  • GlobeNewswire15 days ago

    Helius Medical Technologies, Inc. Announces Third Collaboration to Implement Clinical Experience Programs with PoNS™ Treatment in the United States

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, entered into an agreement in December 2018 to collaborate with Oregon Health & Science University (OHSU) in Portland, Oregon for launch of  its third Clinical Experience Program (CEP) for its Portable Neuromodulation Stimulator (PoNS™). PoNS is a licensed class II medical device in Canada and an investigational medical device in the U.S. and in the EU. PoNS is currently under review for U.S. market clearance by the Food & Drug Administration (FDA) and EU market clearance by the EU Notified Body.

  • Read This Before Selling Helius Medical Technologies, Inc. (NASDAQ:HSDT) Shares
    Simply Wall St.24 days ago

    Read This Before Selling Helius Medical Technologies, Inc. (NASDAQ:HSDT) Shares

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...

  • GlobeNewswirelast month

    Helius Medical Technologies, Inc. Submits CE Mark Application for PoNS™ Device

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, has submitted an application for a CE Mark, the receipt of which will allow the Company to market its Portable Neuromodulation Stimulator (PoNS™) in the European Union. PoNS is a licensed class II medical device in Canada and an investigational medical device in the U.S. and the European Union. “Helius is pleased to continue our exciting pace of progress with respect to our regulatory strategy with the submission of this important application during the fourth quarter,” said Philippe Deschamps, Helius’ Chief Executive Officer.

  • GlobeNewswirelast month

    Helius Medical Technologies, Inc. Announces Exercise of Underwriters’ Overallotment Option

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”) announced today that the underwriters of its previously announced public offering of 2,121,212 shares of Class A common stock which closed on November 19, 2018, have exercised their overallotment option to purchase an additional 318,182 shares of Class A common stock. The offering price to the public was $8.25 per share of Common Stock, and the underwriters purchased the shares from the Company pursuant to the Underwriting Agreement at a price of $7.755 per share. The Company has now sold a total of 2,439,394 shares of Class A common stock in connection with this offering, raising gross proceeds of approximately $20.1 million and estimates net proceeds of approximately $18.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind iPic Entertainment, Smith Micro Software, Northern Technologies International, Intevac, Helius Medical Technologies, and Osiris Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Helius Medical Technologies, Inc. Announces Pricing of Public Offering of Class A Common Stock

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”) today announced the pricing of an underwritten public offering of 2,121,212 shares of its Class A common stock at a public offering price of $8.25 per share, before underwriting discounts and commissions. The net proceeds to Helius from this offering, after deducting the underwriting discounts, commissions and estimated offering expenses payable by Helius, are expected to be approximately $15.7 million. The offering is expected to close on or about Monday, November 19, 2018, subject to customary closing conditions including the approval of the Toronto Stock Exchange. BTIG, LLC and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering.

  • GlobeNewswire2 months ago

    Helius Medical Technologies, Inc. Reports Third Quarter 2018 Financial Results

    NEWTOWN, Pa., Nov. 08, 2018 -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness,.

  • GlobeNewswire3 months ago

    Helius Medical Technologies to Present at the 12th Annual Canaccord Medical Technologies & Diagnostics Forum

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the 12th Annual Canaccord Medical Technologies & Diagnostics Forum at the Westin Grand Central Hotel in New York, New York. A live audio webcast of the conference presentation will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. Helius Medical Technologies is a neurotech company focused on neurological wellness.

  • GlobeNewswire3 months ago

    Helius Medical Technologies, Inc. Announces Second Partnership to Implement Clinical Experience Programs with PoNS™ Treatment in the United States

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, has partnered with Northwell Health’s Feinstein Institute for Medical Research in Manhasset, NY. This partnership will enable Helius to implement its second Clinical Experience Program (CEP) for its Portable Neuromodulation Stimulator (PoNS™) -- an investigational medical device in the US currently under review for market clearance by the US Food & Drug Administration. PoNS is a licensed class II medical device in Canada.

  • GlobeNewswire3 months ago

    Helius Medical Technologies Receives Medical Device License Clearance from Health Canada for PoNS™ Device

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its wholly owned subsidiary, NeuroHabilitation Corporation, received authorization from Health Canada to market its Portable Neuromodulation Stimulator (PoNS™), a class II medical device in Canada. The Health Canada Medical Device License certifies the PoNS Device meets all Canadian safety, effectiveness, and quality requirements. The Canadian Medical Device License approval was preceded by the Company’s achievement of ISO 13485 Certification, the international standard for medical device quality management systems.

  • GlobeNewswire4 months ago

    Helius Medical Technologies and HealthTech Connex Announce Alliance to Build Canadian Commercial Infrastructure

    HealthTech Connex Inc., a Canadian innovative healthcare company and Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius”), a neurotech company focused on neurological wellness, today announced that the Company has entered into an agreement with HealthTech Connex, Inc. (“HTCI”) to develop and manage neuroplasticity clinics in Canada. “The joint venture agreement to establish a new entity called Heuro Canada is an important step in establishing the commercial infrastructure for both the PoNS™ Treatment and the NeuroCatch™ Platform brain measurement in Canada,” said Kirk Fisher, CEO of HealthTech Connex.

  • Who Are The Top Investors In Helius Medical Technologies Inc (NASDAQ:HSDT)?
    Simply Wall St.4 months ago

    Who Are The Top Investors In Helius Medical Technologies Inc (NASDAQ:HSDT)?

    Every investor in Helius Medical Technologies Inc (NASDAQ:HSDT) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual toRead More...